RayzeBio
lead clinical indication refractory tumors nets tumors of the tract net and pancreas net have limited als gses | RayzeBio
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
12 of 41
Related slides by other companies
argenx SE
Results
July 2021
data support favorable benefit to risk ratio four indications clinical proof of concept in no evidence of dose limiting | argenx SE
Talkspace
SPAC
January 2021
science based approach leads to superior clinical outcome | Talkspace
23andMe
Investor Presentation
January 2024
next steps | 23andMe
BioAtla
Investor Presentation
August 2022
phase results with support advancing into phase | BioAtla
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io